Second Affiliated Hospital, Zhejiang University, School of Medicine
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
diagnosed moderate-to- severe IBD patients
defiened as difficult-to-treat(failed from at least two types of biologics or small molecular drugs, or refractory from at least twice of intestinal surgery)
with complete bone-marrow and organic function
no pregnant or planning to become pregnant
welling to paticipate
You may not be if
patients with active infections or latent infections, malignant tumors, recent serious infections(within two weeks)
patients paticipated other clinical trials with four weeks
patients with drug combination other than low-dose glucocotiod
patients recieved abdominal surgery or live vaccine
patients with planned surgery in three months
unsuitable situations determined by researchers
Clareo Health | Safety and Efficiency of the Universal CNK-UT009 in Difficult-to-treat Inflammatory Bowel Disease Patients
